iCAD to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
NASHUA,
N.H., February 8, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced the Company will participate in the virtual BTIG MedTech, Digital
Health, Life Science & Diagnostic Tools Conference from February 15-17,
2022.
Stacey
Stevens, President and incoming CEO of iCAD, is scheduled to participate in a
fireside chat, hosted by research analyst Marie Thibault, on Tuesday, February
15, 2022, at 4:00 p.m. EST. This is a BTIG hosted event and will not be
webcast. Please contact your BTIG
representative for further information.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD® is
a global medical technology leader providing innovative cancer detection and
therapy solutions. For more information, visit www.icadmed.com and www.xoftinc.com.
Forward-Looking Statements
Certain statements contained in this
News Release constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements about
the expected benefits of the Company’s new directors. Such forward-looking
statements involve a number of known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements of the
Company to be materially different from any prior results, performance or
achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited, to the Company’s ability to achieve
positive results from this or any future studies, business and strategic
objectives, the ability of IORT to provide flexibility, mobility or other
advantages, to be more beneficial for patients than traditional therapy or to
be accepted by patients or clinicians, the impact of supply and manufacturing
constraints or difficulties, product market acceptance, possible technological
obsolescence of products, increased competition, litigation and/or government
regulation, changes in Medicare or other reimbursement policies, risks relating
to our existing and future debt obligations, competitive factors, the effects
of a decline in the economy or markets served by the Company; and other risks
detailed in the Company’s filings with the Securities and Exchange Commission.
The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,”
“continue,” “anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
Investor Relations:
Brian Ritchie, LifeSci Advisors
+1-212-915-2578